LLY250509P795000
- 23.95
- -2.21-8.45%
Eli Lilly and Co Newsroom
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers
Jim Cramer Says Eli Lilly and Company (LLY) CEO David Ricks Is 'Very Conservative'
Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook
Novo Nordisk Cuts 2025 Outlook. But Why Are Its Shares Rising?
Novo Nordisk Cuts Guidance as Weight-Loss Drug Sales Slow. Why the Stock Is Jumping. -- Barrons.com
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Eli Lilly and Co Options Spot-On: On May 6th, 75,658 Contracts Were Traded, With 297.3K Open Interest
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com
Eli Lilly Stock Is Sliding Tuesday: What's Going On?
Drug Stocks Hit By D.C. Developments -- Market Talk
Trump Administration Cancels Meeting With FDA Workers Union - Report
Eli Lilly (NYSE:LLY) Declares US$1.50 Second Quarter Dividend For 2025
Eli Lilly (LLY) Raises Dividend by 15%, Maintains Shareholder Payout for 55th Consecutive Year
New Analyst Forecast: $LLY Given $1050.0 Price Target
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. -- Barrons.com
Eli Lilly in Licensing Pact With Alchemab for ALS Program
Alchemab Therapeutics Signs Landmark $415m Licensing Agreement for ATLX-1282 With Eli Lilly and Company
'Trump To Sign Order To Encourage Domestic Drug Manufacturing' - Washington Post
Eli Lilly and Co To Go Ex-Dividend On May 16th, 2025 With 1.5 USD Dividend Per Share
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $944